Table 7 Respiratory medicines prescribed in the 12 months prior to Ext-SLS consent, as recorded in primary care HER.

From: Extending the data collection from a clinical trial: The Extended Salford Lung Study research cohort

 

Asthma (N = 798)

COPD (N = 349)

Treatment, n (%)

SABA

662 (83.0)

314 (90.0)

SAMA

4 (<1)

15 (4.3)

SABA/SAMA (fixed-dose combination)

0

2 (<1)

SABD

663 (83.1)

315 (90.3)

ICS alone (single inhaler)

170 (21.3)

32 (9.3)

LABA alone (single inhaler)

41 (5.1)

33 (9.5)

LAMA alone (single inhaler)

59 (7.4)

250 (71.6)

ICS/LABA (FDC)

619 (77.6)

306 (87.7)

LABA/LAMA (FDC)

2 (<1)

32 (9.2)

ICS/LABA/LAMA (single inhaler)

27 (3.4)

87 (24.9)

LTRA

122 (15.3)

14 (4.0)

Methylxanthine

3 (<1)

8 (2.3)

PD4, theophylline

1 (<1)

4 (1.2)

Chronic OCS usea

21 (2.6)

27 (7.7)

  1. COPD chronic obstructive pulmonary disease, EHR electronic health record, Ext-SLS extended Salford Lung Study, FDC fixed-dose combination, ICS inhaled corticosteroid, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, LTRA leukotriene receptor antagonists, OCS oral corticosteroid, PD4 phosphodiesterase 4, SABA short-acting β2-agonist, SABD short-acting bronchodilator, SAMA short-acting muscarinic antagonist, SD standard deviation, SLS Salford Lung Study.
  2. aChronic OCS use defined as at least 4 courses with no gaps greater than 30 days; groups are not mutually exclusive.
Back to article page